Targeted therapies for the treatment of soft tissue sarcoma
Soft tissue sarcomas are rare malignant tumors derived from mesenchymal cells that have a high morbidity and mortality related to frequent occurrence of advanced and metastatic disease. Over the past two decades there have been significant advances in the use of targeted therapies for the treatment...
Main Authors: | Jeffrey W. Fuchs, Brian C. Schulte, Joseph R. Fuchs, Mark Agulnik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1122508/full |
Similar Items
-
Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma
by: Joseph R. Fuchs, et al.
Published: (2023-01-01) -
The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
by: Ren‐Shu Zhang, et al.
Published: (2022-06-01) -
Targeted therapy for soft tissue sarcomas in adolescents and young adults
by: Steppan DA, et al.
Published: (2017-03-01) -
Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy
by: Xin-Hui Du, et al.
Published: (2020-09-01) -
The Role of Trabectedin in Soft Tissue Sarcoma
by: Tomoki Nakamura, et al.
Published: (2022-02-01)